Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.47
+0.47002.76%
Volume:1.23M
Turnover:21.46M
Market Cap:13.94B
PE:-15.63
High:17.68
Open:17.20
Low:17.14
Close:17.00
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.36
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:22.12
PE(LYR):-12.10

Loading ...

S&P 500 Futures Climb In Premarket Trading; WR Berkley, Summit Therapeutics Lag

Dow Jones
·
May 22

Summit Therapeutics Plc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
May 22

U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday

Reuters
·
May 22

Used EV sales soar as drivers look to curb fuel costs

cityam
·
May 12

Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply

Simply Wall St.
·
May 11

Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns

Stock Track
·
May 08

Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations

Stock Track
·
May 04

Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio?

Benzinga_recent_news
·
May 03

Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?

Simply Wall St.
·
May 03

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)

TIPRANKS
·
May 03

Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 03

Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing

TIPRANKS
·
May 02

Summit Therapeutics Shares Fall After 1Q Loss Widens

Dow Jones
·
May 02

BUZZ-Summit Therapeutics falls after interim results from lung cancer study

Reuters
·
May 02

Summit Therapeutics Stock Dips After Q1 Financial Report

Benzinga Earnings
·
May 01

Summit Therapeutics falls -27.4%

TIPRANKS
·
May 01

Goldman Sachs Remains a Buy on Summit Therapeutics (SMMT)

TIPRANKS
·
May 01

Summit Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 01

Summit Therapeutics Q1 FY26 net loss widens to $189.4 million; operating expenses rise to $195.2 million

Reuters
·
May 01

Summit Therapeutics Q1 adjusted loss narrows despite higher R&D costs

Reuters
·
May 01